Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
HCWB Stock Forecast 2026-2027
$0.44
Current Price
$2.94M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to HCWB Price Targets
+357.7%
To High Target of $2.00
+357.7%
To Median Target of $2.00
+357.7%
To Low Target of $2.00
HCWB Price Momentum
+25.7%
1 Week Change
-40.5%
1 Month Change
-93.8%
1 Year Change
-54.6%
Year-to-Date Change
-97.5%
From 52W High of $17.80
+74.8%
From 52W Low of $0.25
📊 TOP ANALYST CALLS
Did HCWB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if HCW Biologics is one of their latest high-conviction picks.
Latest HCWB Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, HCWB has a bullish consensus with a median price target of $2.00 (ranging from $2.00 to $2.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $0.44, the median forecast implies a 357.7% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HCWB Analyst Ratings
1
Buy
0
Hold
0
Sell
HCWB Price Target Range
Low
$2.00
Average
$2.00
High
$2.00
Current: $0.44
Latest HCWB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HCWB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 29, 2025 | Maxim Group | Michael Okunewitch | Buy | Maintains | $35.00 |
| Jun 1, 2023 | EF Hutton | Tony Butler | Buy | Assumes | $9.00 |
| Apr 19, 2023 | EF Hutton | Constantine Davides | Buy | Reiterates | $9.00 |
| Mar 30, 2023 | EF Hutton | Constantine Davides | Buy | Reiterates | $9.00 |
| Mar 23, 2023 | EF Hutton | Constantine Davides | Buy | Reiterates | $9.00 |
| Nov 8, 2022 | JonesTrading | Soumit Roy | Buy | Initiates | $8.00 |
| Mar 24, 2022 | Maxim Group | Michael Okunewitch | Buy | Initiates | $4.00 |
| Nov 19, 2021 | EF Hutton | Buy | Initiates | $N/A |
HCW Biologics Inc. (HCWB) Competitors
The following stocks are similar to HCW Biologics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
HCWB
HCW Biologics
mkt cap
2.94M
HCW Biologics Inc. (HCWB) Financial Data
HCW Biologics Inc. has a market capitalization of $2.94M with a P/E ratio of 0.0x. The company generates $54,232 in trailing twelve-month revenue with a 20.0% profit margin.
Revenue growth is -93.2% quarter-over-quarter, while maintaining an operating margin of -18,370.3% and return on equity of -806.5%.
Valuation Metrics
Market Cap
$2.94M
Enterprise Value
$7.80M
P/E Ratio
0.0x
PEG Ratio
-0.8x
Price/Sales
54.3x
Growth & Margins
Revenue Growth (YoY)
-93.2%
Gross Margin
+20.0%
Operating Margin
-18,370.3%
Net Margin
+20.0%
EPS Growth
-93.2%
Financial Health
Cash/Price Ratio
+66.4%
Current Ratio
0.1x
Debt/Equity
246.3x
ROE
-806.5%
ROA
-31.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
HCW Biologics Inc. (HCWB) Business Model
About HCW Biologics Inc.
What They Do
Develops novel immunotherapies targeting age-related diseases.
Business Model
HCW Biologics operates as a clinical-stage biopharmaceutical company, generating revenue through the development of innovative immunotherapies that address chronic inflammation linked to aging. The company utilizes proprietary platforms to create multi-functional fusion molecules, with a robust pipeline of over 50 candidates currently in clinical trials, focusing on oncology and autoimmune disorders.
Additional Information
Founded in 2018 and based in Miramar, Florida, HCW Biologics collaborates with partners like Wugen Inc. for cell therapy manufacturing and has a joint venture with WY Biotech. As a publicly traded entity, the company is positioned to capitalize on the growing demand for advanced therapeutic solutions in the biopharmaceutical industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
36
CEO
Dr. Hing C. Wong Ph.D.
Country
United States
IPO Year
2021
Website
www.hcwbiologics.comHCW Biologics Inc. (HCWB) Latest News & Analysis
Latest News
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results
19 days ago
Quick Summary
HCW Biologics Inc. (NASDAQ: HCWB) reported its Q4 financial results for 2025, focusing on its development of fusion immunotherapeutics for chronic inflammation-related diseases.
Why It Matters
HCW Biologics' Q4 financial results and business updates can impact stock performance, indicating growth potential and market positioning in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A new commercialization-ready compound enhances the generation of highly functional human CAR-T cells, offering potential advancements in treating infectious diseases and cancer.
Why It Matters
The development of a new CAR-T cell generation method could lead to effective treatments for cancer and infectious diseases, potentially transforming the biotech landscape and driving stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic
1 month ago
Quick Summary
A total upfront cash fee of $7.0 million has been announced, consisting of a $3.5 million cash payment and a $3.5 million in transferable equity interest in the licensee.
Why It Matters
The $7 million upfront fee indicates strong financial backing and potential for future returns, signaling confidence in the asset's value and growth prospects, impacting investment decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter
1 month ago
Quick Summary
HCW Biologics Inc. (Nasdaq: HCWB) has regained compliance with Nasdaq listing rules, as confirmed by the Nasdaq Hearings Panel on February 26, 2026.
Why It Matters
Regaining compliance with Nasdaq listing rules boosts HCW Biologics' credibility and stability, enhancing investor confidence and potentially attracting more capital.
Source: GlobeNewsWire
Market Sentiment:
Neutral
HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
2 months ago
Quick Summary
HCW Biologics Inc. (NASDAQ: HCWB) announced a follow-on offering of 2,477,292 units at $0.6055 each. Each unit includes one share and a warrant. Closing expected by February 19, 2026.
Why It Matters
HCW Biologics' follow-on offering indicates capital raising efforts, potentially diluting existing shares, while also providing funds for R&D in immunotherapies. Market reaction may impact share price.
Source: GlobeNewsWire
Market Sentiment:
Neutral
HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune
2 months ago
Quick Summary
HCW Biologics receives $7M and shares from Trimmune for exclusive rights to a preclinical molecule. Phase 1 study is set for H1 2027, with HCW retaining a royalty-free option for the Americas.
Why It Matters
HCW Biologics' licensing deal with Trimmune enhances its pipeline and potential revenue streams, while the upcoming Phase 1 study could drive investor interest and stock valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About HCWB Stock
What is HCW Biologics Inc.'s (HCWB) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, HCW Biologics Inc. (HCWB) has a median price target of $2.00. The highest price target is $2.00 and the lowest is $2.00.
Is HCWB stock a good investment in 2026?
According to current analyst ratings, HCWB has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.44. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HCWB stock?
Wall Street analysts predict HCWB stock could reach $2.00 in the next 12 months. This represents a 357.7% increase from the current price of $0.44. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is HCW Biologics Inc.'s business model?
HCW Biologics operates as a clinical-stage biopharmaceutical company, generating revenue through the development of innovative immunotherapies that address chronic inflammation linked to aging. The company utilizes proprietary platforms to create multi-functional fusion molecules, with a robust pipeline of over 50 candidates currently in clinical trials, focusing on oncology and autoimmune disorders.
What is the highest forecasted price for HCWB HCW Biologics Inc.?
The highest price target for HCWB is $2.00 from at , which represents a 357.7% increase from the current price of $0.44.
What is the lowest forecasted price for HCWB HCW Biologics Inc.?
The lowest price target for HCWB is $2.00 from at , which represents a 357.7% increase from the current price of $0.44.
What is the overall HCWB consensus from analysts for HCW Biologics Inc.?
The overall analyst consensus for HCWB is bullish. Out of 5 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $2.00.
How accurate are HCWB stock price projections?
Stock price projections, including those for HCW Biologics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 20, 2026 2:56 PM UTC